Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7648594 | 0.79 | LMNA (0.46) | ALDH1A1MAPTALOX15HSD17B10PSMD14 | |
| SCHEMBL3259063 | 0.77 | TSHR (0.62) | ALDH1A1MAPTHSD17B10LMNATSHR | |
| SCHEMBL11841692 | 0.76 | CCNE2 (0.43) | ALDH1A1MAPTALOX15HSD17B10PSMD14 | |
| SCHEMBL523863 | 0.72 | MAPT (0.49) | ALDH1A1MAPTALOX15HSD17B10PSMD14 | |
| SCHEMBL9148337 | 0.72 | LMNA (0.85) | ALDH1A1MAPTALOX15HSD17B10PSMD14 | |
| SCHEMBL1424601 | 0.71 | ALOX15 (0.66) | ALDH1A1MAPTALOX15HSD17B10PSMD14 | |
| SCHEMBL182010 | 0.71 | CES2 (0.71) | ALDH1A1ALOX15HSD17B10HPGDLMNA | |
| SCHEMBL14688364 | 0.70 | HPGD (0.50) | ALDH1A1MAPTALOX15HSD17B10PSMD14 | |
| SCHEMBL4264795 | 0.70 | NAPRT (0.54) | ALDH1A1MAPTALOX15HSD17B10PSMD14 | |
| SCHEMBL4414573 | 0.70 | ALDH1A1 (0.50) | ALDH1A1MAPTALOX15HSD17B10PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008486-B2 | Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound | FERRER INTERNACIONAL, S.A. (ES) | 2011-08-30 | — | — | US | claimed |
| EP-2081934-B1 | PROCESS FOR THE MANUFACTURE OF A CRYSTALLINE PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND | FERRER INT (ES) | 2011-03-30 | — | — | EP | claimed |
| US-20100048896-A1 | PROCESS FOR THE MANUFACTURE OF A CRYSTALLINE PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND | FERRER INTERNACIONAL, S.A. (ES) | 2010-02-25 | — | — | US | claimed |
| EP-2081934-A1 | PROCESS FOR THE MANUFACTURE OF A CRYSTALLINE PYRAZOLOÝ1,5-A¨PYRIMIDINE COMPOUND | Ferrer Internacional, S.A. (ES) | 2009-07-29 | — | — | EP | claimed |
| EP-1956021-A1 | Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-13 | — | — | EP | claimed |
| WO-2008043799-A1 | PROCESS FOR THE MANUFACTURE OF A CRYSTALLINE PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND | FERRER INTERNACIONAL, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | FERRER INTERNACIONAL, S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACTIONAL, S.A. (ES) | 2016-12-22 | — | — | US | disclosed |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACTIONAL, S.A. (ES) | 2016-12-22 | — | — | US | disclosed |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACTIONAL, S.A. (ES) | 2016-12-22 | — | — | US | disclosed |
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACTIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-8530482-B2 | Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-09-10 | — | — | US | disclosed |
| CN-1829719-A | N- [ 3- (3-substituted-pyrazolo [1, 5-a ] pyrimidin-7-yl) phenyl ] -sulfonamides, compositions thereof, and related methods | FERRER INT (ES) | 2006-09-06 | — | — | CN | disclosed |
| EP-1648897-A1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033796-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | WYETH | 2006-03-23 | — | — | US | disclosed |
| WO-2005014597-A1 | N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885MAPT 2417/4885ALOX15 1284/4885 |
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | GABRA5, GABRA1, GABBR1 | ALDH1A1 502/4885MAPT 2291/4885ALOX15 1414/4885 |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885MAPT 2417/4885ALOX15 1284/4885 |
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | TYMP, DPYD, TYMS | ALDH1A1 848/4885MAPT 3174/4885ALOX15 2579/4885 |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885MAPT 2417/4885ALOX15 1284/4885 |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | TYMP, DPYD, TYMS | ALDH1A1 847/4885MAPT 4164/4885ALOX15 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.